S. 2149Senate117th Congress (2021-2023)In Committee

Donald Payne, Sr., Colorectal Cancer Detection Act of 2021

Introduced June 21, 2021

AI-Generated Summary

Updated February 8, 2026 at 4:36 AM UTC

The Donald Payne, Sr., Colorectal Cancer Detection Act of 2021 amends the Social Security Act to add coverage under Medicare for FDA‑approved blood‑based tests that screen for colorectal cancer. It aims to boost screening rates in communities that have been under‑screened, especially after declines caused by the COVID‑19 pandemic, and to set payment rules for these new tests.

Key Provisions

  • Adds a new category called “qualifying colorectal cancer screening blood‑based test” to Medicare’s covered services list.
  • Defines a qualifying test as an FDA‑approved blood test for early detection of colorectal cancer that has been marketed or used at least six months before the start of the coverage year.
  • Allows the Secretary of Health and Human Services to set the payment amount for these blood‑based screening tests.
  • Extends existing frequency limits for colorectal cancer screening to include the new blood‑based tests, aligning them with limits for fecal‑occult blood tests and other procedures.
  • Specifies that the changes apply to tests furnished more than six months after the law’s enactment.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateIntro Referral Latest Action

Read twice and referred to the Committee on Finance.

June 21, 2021

View full timeline
SenateIntro Referral

Introduced in Senate

June 21, 2021

SenateIntro Referral

Read twice and referred to the Committee on Finance.

June 21, 2021

Floor Debate

1 member

What members said about S. 2149 on the floor

1 Democrat

Madam Speaker, on September 16, the United States District Court for the Northern Mariana Islands will be officially moved into its new courtroom and offices in Gualo Rai on the island of Saipan. The…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued June 21, 2021

II

117th CONGRESS

1st Session

S. 2149

IN THE SENATE OF THE UNITED STATES

June 21, 2021

Mr. Heinrich (for himself, Mr. Wicker, and Mr. Padilla) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, to increase participation in colorectal cancer screening in under-screened communities of color, to offset the COVID–19 pandemic driven declines in colorectal cancer screening, and for other purposes.

1.

Short title

This Act may be cited as the Donald Payne, Sr., Colorectal Cancer Detection Act of 2021.

2.

Medicare coverage for FDA-approved qualifying colorectal cancer screening blood-based tests

(a)

In general

Section 1861(pp) of the Social Security Act (42 U.S.C. 1395x(pp)) is amended—

(1)

in paragraph (1)—

(A)

by redesignating subparagraph (D) as subparagraph (E); and

(B)

by inserting after subparagraph (C) the following new subparagraph:

(D)

Qualifying colorectal cancer screening blood-based test.

; and

(2)

by adding at the end the following new paragraph:

(3)

The term qualifying colorectal cancer screening blood-based test means, with respect to a year, a screening blood-based test for the early detection of colorectal cancer furnished in the year that was marketed or used, as applicable, in accordance with the relevant provisions of section 353 of the Public Health Service Act or the Federal Food, Drug, and Cosmetic Act more than 6 months before the beginning of the year.

.

(b)

Frequency limits for colorectal cancer screening tests and payment amount for qualifying colorectal cancer screening blood-Based tests

Section 1834(d) of the Social Security Act (42 U.S.C. 1395m(d)) is amended—

(1)

by amending clause (ii) of paragraph (1)(B) to read as follows:

(ii)

if the test is performed within—

(I)

the 11 months after a previous screening fecal-occult blood test or a previous qualifying colorectal cancer screening blood-based test;

(II)

the 35 months after a previous screening flexible sigmoidoscopy or a previous screening colonoscopy with adenoma findings;

(III)

the 59 months after a previous screening colonoscopy with small polyp findings; or

(IV)

the 119 months after a previous screening colonoscopy without adenoma findings or small polyp findings.

;

(2)

in paragraph (2)(E)(ii), by inserting or within the 35 months after a previous screening fecal-occult blood test or previous qualifying colorectal cancer screening blood-based test after sigmoidoscopy;

(3)

by amending subparagraph (E) of paragraph (3) to read as follows:

(E)

Frequency limit

No payment may be made under this part for a colorectal cancer screening test consisting of a screening colonoscopy—

(i)

if the procedure is performed within the 11 months after a previous screening fecal-occult blood test or previous qualifying colorectal cancer screening blood-based test;

(ii)

for individuals at high risk for colorectal cancer if the procedure is performed within the 23 months after a previous screening colonoscopy; or

(iii)

for individuals not at high risk for colorectal cancer if the procedure is performed within the 119 months after a previous screening colonoscopy or within the 47 months after a previous screening flexible sigmoidoscopy.

; and

(4)

by adding at the end the following new paragraph:

(4)

Qualifying colorectal cancer screening blood-based tests

(A)

Payment amount

The payment amount for colorectal cancer screening tests consisting of qualifying colorectal cancer screening blood-based tests shall be established by the Secretary.

(B)

Frequency limit

Paragraph (1)(B) shall apply to colorectal cancer screening tests consisting of qualifying colorectal cancer screening blood-based tests in the same manner as such paragraph applies to colorectal cancer screening tests consisting of fecal-occult blood tests.

.

(c)

Effective date

The amendments made by this section shall apply to colorectal cancer screening tests furnished in a year beginning more than 6 months after the date of the enactment of this Act.